Skye Bioscience
SKYE
71 hedge funds and large institutions have $39.3M invested in Skye Bioscience in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 7 closing their positions.
300% more call options, than puts
Call options by funds: $84K | Put options by funds: $21K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more funds holding
Funds holding: 65 → 71 (+6)
3.36% less ownership
Funds ownership: 83.09% → 79.73% (-3.4%)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
45% less capital invested
Capital invested by funds: $71.3M → $39.3M (-$32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$531K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$253K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$251K |
| 4 |
LPL Financial
San Diego,
California
|
+$217K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$95.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$708K |
| 2 |
ACM
Altium Capital Management
New York
|
-$639K |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$384K |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$250K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$241K |
SKYE Hedge Fund Activity: Q1 2025 in Review
71 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q1 2025, worth a combined $39.3M — down 45% from $71.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SKYE positions and 7 closed out — a net gain of 7 holders — while 16 added to existing stakes and 19 trimmed.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $531K. The largest seller was Citadel Advisors, exiting entirely with an estimated $708K sold.
- 71 institutional investors held Skye Bioscience (SKYE) as of Q1 2025, up from 65 in Q4 2024.
- Funds reported $39.3M of Skye Bioscience stock for Q1 2025, down 45% quarter-over-quarter.
- 14 funds opened new Skye Bioscience positions in Q1 2025 and 7 closed out, a net change of +7 holders.
- The largest Skye Bioscience buyer in Q1 2025 was Schonfeld Strategic Advisors, an estimated $531K added.
- The largest Skye Bioscience seller in Q1 2025 was Citadel Advisors, an estimated $708K sold.
Based on aggregated 13F filings for Q1 2025.